SCHEMBL6985384

SCHEMBL6985384

CC1=CC(=O)CC(c2ccc(Cl)c(Cl)c2)N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.40
SLC6A2 P23975 11/20 0.40
SLC6A3 Q01959 11/20 0.40
SLC6A4 P31645 5/20 0.38
MAOB P27338 3/20 0.35
CYP2D6 P10635 2/20 0.35
KCNH2 Q12809 1/20 0.35
TP53 P04637 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
THPO P40225 1/20 0.35
MTOR P42345 1/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982349 0.83 POLB (0.46) SLC6A2SLC6A3SLC6A4CYP2D6TP53
SCHEMBL6981391 0.81 MAPT (0.43) SLC6A2SLC6A3TP53TSHRLMNA
SCHEMBL6985757 0.81 MAPT (0.43) SLC6A2SLC6A3TP53TSHRLMNA
SCHEMBL6978662 0.81 MAPT (0.43) SLC6A2SLC6A3TP53TSHRLMNA
SCHEMBL7814746 0.79 BACE1 (0.51) BACE1SLC6A2SLC6A3SLC6A4CYP2D6
SCHEMBL6979945 0.76 BRD4 (0.45) MAPK1LMNAPOLB
SCHEMBL6979158 0.74 TP53 (0.42) SLC6A3TP53TSHRPOLB
SCHEMBL6984495 0.72 DDB1 (0.45) NPC1LMNA
SCHEMBL6988020 0.69
SCHEMBL14458003 0.68 PDE4A (0.48) BACE1SLC6A2SLC6A3SLC6A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed
EP-1050530-A1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers ADIR ET COMPAGNIE (FR) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 BACE1 571/4885SLC6A2 1246/4885SLC6A3 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.